@pharmdaz@jy201506 She says once they zero in on its niche (ie. Stay away from HER2 & KRAS mutation) and she believes the extra logistical steps will greatly win over the more toxic less durable options of ADCs.
@pharmdaz@jy201506 Yes, the natural way is always better and less toxic but IOV has got to find its sweet spot to drive efficacy and earn a 1st line status. The issues to overcome: 1) target the right biomarkers
2) figure out a meaningful injection schedule = proven durability = they win.
@DeuceCabooseSki Not at all. I am pissed. No way Wayne didn’t know this would happen. New CMO knew this when he got the 450k shares at 14.82. We aren’t getting all the info.
@pharmdaz Just curious how u split your money between these 12? Think IOVA teases the crowd with anything new at ESMO today in 1L Melanoma? Thx. Hope you have a great Friday.